The pharmacodynamics of i.v. and subcutaneous (s.c.) tinzaparin sodium compared with heparin in healthy volunteers were studied. A randomized, open-label, five-treatment, five-period-crossover study ...

Hospitalization rate differences among cancer patients on biologics and biosimilars. HTB patients with active LC related to 4 factors: disease, treatment, biomarker and patient features.

Prospective and working memory decline as a result of impaired sleep and/or impared blood glucose in breast cancer patients during chemotherapy treatment. Background: VTE is a major cause of morbidity ...

The inhibitory effect of anti-thrombin III (AT-III) on thrombin, factor IIa and other coagulation serine proteases in plasma is increased several thousand-fold by Tinzaparin. This inhibition accounts ...

Assays were linear over the range from 0.0 to 1 IU/mL for anti-Xa activity (mean r = 0.994 [n = 114], range = 0.995-1.0) and from 0 to 0.4 IU/mL for anti-IIa activity (mean r = 0.9963 [n = 71], range ...